Harris · The American journal of clinical nutrition 2007 · randomized controlled trial · n=?

Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids.

Cited 180 times in the scientific literature.

Level 2 - randomized trial

Individual randomized controlled trial

PubMed 18065578 · doi:10.1093/ajcn/86.5.1621 · record verified 2026-08-30

What was done

Healthy premenopausal female volunteers were randomized to receive a daily average of 485 mg EPA and DHA from either two servings of oily fish (salmon and albacore tuna) per week or 1–2 fish-oil capsules per day for 16 weeks. The rate and extent of EPA and DHA enrichment in red blood cell (RBC) membranes and plasma phospholipids were compared between the two groups.

What was found

After 16 weeks, RBC EPA+DHA increased from 4.0 ± 0.6% to 6.2 ± 1.4% in the fish group (n = 11) and from 4.3 ± 1.0% to 6.2 ± 1.4% in the capsule group (P < 0.0001 for both within-group increases; not significant for group effect). Similar results occurred in plasma phospholipids, which stabilized at 4 weeks, whereas RBC levels increased through week 16. RBC EPA increased significantly faster in the fish group during the first 4 weeks (P = 0.01), with no significant group difference in rate thereafter. Total fatty acid variances were lower in RBCs than in plasma phospholipids (P = 0.04).

Why it matters

This study shows that consuming EPA and DHA through weekly dietary fish is as bioavailable and effective for tissue fatty acid enrichment as taking daily fish-oil supplements.

Limits

The total sample size is small (fish group n = 11; capsule group n not stated in the abstract). The study included only healthy premenopausal females, limiting direct generalization to other populations, and dietary interventions cannot be blinded.

Cited by